AKT1 and Proteus syndrome: Moreover, miransertib is currently undergoing a phase II trial (NCT04316546) to treat a rare but progressive overgrowth syndrome (Proteus syndrome) that arises from the E17K mutation in Akt, with case reports showing single-agent activity (52–54).